WHG
PCRX icon

Westwood Holdings Group’s Pacira BioSciences PCRX Stock Holding History

Westwood Holdings Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,030
Closed -$480K – 590
2022
Q3 		$480K Buy
+9,030
New +$502K 0.01% 370

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Westwood Holdings Group's PCRX Position: Q4 2022 in Review

Westwood Holdings Group sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 9,030 shares — an estimated $480K sold.

Westwood Holdings Group first reported a position in PCRX in Q3 2022 and held it in 1 quarter. The position peaked at $480K in Q3 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Westwood Holdings Group reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • Westwood Holdings Group sold 9,030 Pacira BioSciences shares in Q4 2022, an estimated $480K.
  • Westwood Holdings Group first reported a position in Pacira BioSciences in Q3 2022 and held it in 1 quarter.
  • Westwood Holdings Group's Pacira BioSciences position peaked at $480K in Q3 2022.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Westwood Holdings Group's 13F filing for Q4 2022, filed 14 Feb 2023.